AETER Puri Eyes™ Polynucleotide Treatment
Medical-grade Periocular Rejuvenation
AETER Puri Eyes™ is a premium polynucleotide formulation for periocular rejuvenation, clinically proven to improve dermal wound closure by 86% and increase collagen density by 73% within 8 weeks. Combining high-purity PN fragments with cross-linked HA, it delivers biomechanical lifting and sustained hydration. CE certified and compliant with ISO 13485 standards for safe ocular applications.
- Biomechanical Lifting: Increases dermal density by 37% through fibroblast activation
- Deep Hydration: Provides sustained 72-hour moisture retention
- Wrinkle Reduction: 86% improvement in fine line appearance within 4 treatments
- Rapid Recovery: 2.3x faster epithelialization compared to standard treatments
Polynucleotides, Hyaluronic Acid
Pre-filled sterile syringes with Luer Lock
Refrigerated; Protect from light
Limited after activation
CE | ISO 13485 | GMP Grade A
Contraindications: Active ocular infections, pregnancy, or allergy to avian products
Ideal Candidates: Patients with mild to moderate wrinkles (Grade 1-3)
Professional Note: Consultation with a dermatologist is mandatory prior to treatment
Special Offer: Christmas Special: Buy 10 Get 1 Free! + Free Eye Patches with Every Purchase!
• AETER Puri Eyes requires administration by licensed practitioners
• Not for self-use or home application
• Always follow aseptic techniques during administration
• Monitor for hypersensitivity reactions during initial treatment
• Manufacturer not liable for improper storage or application errors
We are an authorized wholesale distributor of medical aesthetic products. This product information is provided for professional healthcare providers only. We do not sell directly to end-users. All products must be administered by qualified medical professionals in accordance with local regulations. Product specifications may vary – please contact us for current detailed specifications. Product images may differ from actual packaging.
Reviews
There are no reviews yet.